Why ImmunoGen, Inc. Fell 10.6% on Thursday
What happened
Shares of ImmunoGen (NASDAQ: IMGN) closed down 10.6% on Thursday on no apparent news. The volatile biotech stock is, well, volatile. It's not exactly the first time we've seen a double-digit move on no news.
So what
ImmunoGen's investors are in a wait mode, having fully enrolled the phase 3 Forward 1 clinical trial testing mirvetuximab as a monotherapy in platinum-resistant ovarian cancer. Data from the trial is expected next year. If positive, the data should be enough to gain regulatory approval for mirvetuximab.
Between now and then, investors can expect some earlier-stage data for mirvetuximab. The phase 2 trial, dubbed Forward 2, will read out data for patients treated with mirvetuximab and Merck's (NYSE: MRK) Keytruda at the European Society for Medical Oncology meeting this month.
And in December, data for ImmunoGen's earlier-stage assets IMGN779 and IMGN632 is expected at the American Society of Hematology meeting. Both drugs are only in phase 1, but they give investors an idea of what could follow after mirvetuximab.
Now what
Long-term investors should ignore the daily gyrations in the stock price and focus on ImmunoGen's clinical trial data. Forward 1 is clearly the most important clinical trial to get mirvetuximab on the market, but other data later this year should tide investors over while they wait.
10 stocks we like better than ImmunoGenWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and ImmunoGen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018The author(s) may have a position in any stocks mentioned.
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends ImmunoGen. The Motley Fool has a disclosure policy.